Erratum.

Abstract

In the article “The 21st Annual Prostate Cancer Foundation Scientific Retreat Report,” published in the August 1, 2015, issue of The Prostate (Prostate 2015;75:1119-1128; DOI 10.1002/pros.22993), there were a number of special characters that were typeset incorrectly. Below is a list; we apologize for the errors. On page 5, left-hand column, the text wrongly reads as follows: Cancer immunotherapy with checkpoint inhibitors such as aCTLA-4 and aPD-1 results in deep, durable clinical responses in melanoma and lung cancer. Correction: Cancer immunotherapy with checkpoint inhibitors such as αCTLA-4 and αPD-1 results in deep, durable clinical responses in melanoma and lung cancer. On page 5, left-hand column, the text wrongly reads as follows: In the KPC mouse, a model in which inducible loss of p53 and overexpression of oncogenic KRASG12D in pancreatic cells leads to the development of pancreatic ductal adenocarcinoma, T cells were found to be specifically excluded from tumor regions and tumors were resistant to treatment with the checkpoint inhibitor aPD-L1. Correction: In the KPC mouse, a model in which inducible loss of p53 and overexpression of oncogenic KRASG12D in pancreatic cells leads to the development of pancreatic ductal adenocarcinoma, T cells were found to be specifically excluded from tumor regions and tumors were resistant to treatment with the checkpoint inhibitor αPD-L1. On page 5, bottom of left-hand column and top of right-hand column, the text wrongly reads as follows: FAP (fibroblast activation protein)-expressing cancer-associated fibroblasts (CAFs) residing in the tumor microenvironment were found to be required for T cell exclusion and aPD-L1 resistance. Correction: FAP (fibroblast activation protein)-expressing cancer-associated fibroblasts (CAFs) residing in the tumor microenvironment were found to be required for T cell exclusion and αPD-L1 resistance. On page 5, right-hand column, the text wrongly reads as follows: T cells express the CXCL12 receptor CXCR4 and treatment with the CXCR4-inhibitor AMD3100 allowed T cell infiltration into tumors and synergized with aPD-L1 in preventing tumor growth. Correction: T cells express the CXCL12 receptor CXCR4 and treatment with the CXCR4-inhibitor AMD3100 allowed T cell infiltration into tumors and synergized with αPD-L1 in preventing tumor growth. On page 6, right-hand column, the text wrongly reads as follows: These observations have led to the initiation of trials combining aPD-1/aPD-L1 with ipilimumab in prostate cancer patients. Correction: These observations have led to the initiation of trials combining αPD-1/αPD-L1 with ipilimumab in prostate cancer patients. On page 8, right-hand column, the text wrongly reads as follows: Gene expression and genomic copy number analysis of individual EpCAM+CD45( cells isolated from patient bone marrow and thought to be prostate DTCs, revealed that cells with this surface marker phenotype comprised either prostate DTCs or erythroid progenitor cells. Correction: Gene expression and genomic copy number analysis of individual EpCAM+CD45− cells isolated from patient bone marrow and thought to be prostate DTCs, revealed that cells with this surface marker phenotype comprised either prostate DTCs or erythroid progenitor cells. On page 9, left-hand column, the text wrongly reads as follows: Treatment of prostate cancer cells with GAS6 prohibited proliferation in vitro and inoculation of tumor cells into GAS6(/( mice resulted in increased primary and bone metastatic tumor growth. Correction: Treatment of prostate cancer cells with GAS6 prohibited proliferation in vitro and inoculation of tumor cells into GAS6−/− mice resulted in increased primary and bone metastatic tumor growth. On page 9, left-hand column, the text wrongly reads as follows: Finally, co-culture of prostate cancer cells with WT but not GAS6(/( osteoblasts increased the proportion… . Correction: Finally, co-culture of prostate cancer cells with WT but not GAS6−/− osteoblasts increased the proportion… .